Genova Biotech (Changzhou) Raises $50 Million in Tasly-led Funding

Genova Biotech of Changzhou raised $50 million in a funding led by Tasly Pharma. Genova is developing state-of-the-art diabetes products which it expects to offer at prices below global diabetes providers. Founded in 2014, the company has in-licensed rights to four products, though no details on the transactions are available. Genova is a JV formed by China investor BVCF and Changzhou Life Sciences & Healthcare Construction and Development. With the latest funding, Genova has raised $200 million in capital. More details.... Share this with colleagues: // //